# Gemelli Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gemelli-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Raleigh, US
- Website: http://www.gemellibiotech.com
- Total disclosed funding: $19M
- Latest round: Series A (Dec 7, 2021)
- Investors on record: 4

## About

Based in North Carolina, US, and founded in 2018 by Matt Mitcho (CEO), Gemelli Biotech Corp. is a provider of equipment that detects gastrointestinal diseases in patients. In June 2022, Gemelli Biotech Corp. raised USD 19 million in series A funding led by new investor Blue Ox Healthcare Partners, with participation from other new investors Carolina Angel Network, Cedars-Sinai Health System, and CerraCap Ventures. The company holds partnerships with Biomedica, Unilabs, Cedars-Sinai, Sibotest, and many more.

The company offers diagnostic equipment namely trio-smart and ibs-smart. Trio-smart is a three-gas breath test equipment, that analyzes the level of hydrogen, methane, and hydrogen sulfide in the patient’s breath and gives a clear picture of gut health, and detects whether it is gas, bloating, constipation, diarrhea, or anything else. Ibs-smart is an ELISA blood test that measures the level of two antibodies i.e. anti-CdtB and anti-vinculin that causes irritable bowel syndrome (IBS).

The company will use the June 2022 funding to commercialize its products and expand its sales and marketing team across the US.

## Funding rounds

- Series A, Dec 7, 2021, $19M — Blue Ox Healthcare Partners, CerraCap Ventures, Carolina Angel Network, Cedars-Sinai Health System

## Investors

- Blue Ox Healthcare Partners (https://capitalatlas.ai/funds/blue-ox-healthcare-partners) — Series A
- CerraCap Ventures (https://capitalatlas.ai/funds/cerracap-ventures) — Series A
- Carolina Angel Network (https://capitalatlas.ai/funds/carolina-angel-network) — Series A
- Cedars-Sinai Health System — Series A